| 标题 |
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of Clinical Oncology 作者:Charles M. Rudin; Maria Catherine Pietanza; Todd Michael Bauer; David R. Spigel; Neal Ready; et al 出版日期:2018-09-06 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)